Submitting to JAMA.

01 About JAMA

JAMA, the Journal of the American Medical Association, is one of the most widely read and cited general medical journals in the world. Published by the American Medical Association, JAMA covers a broad scope of clinical medicine, health professions, and biomedical research, with particular depth in areas including neurology, pharmacology, and the economics of health and healthcare delivery. The journal's top conceptual domains (medicine, health professions, and economics and econometrics) reflect its dual commitment to clinical science and the policy and economic dimensions of healthcare.

With a catalog of 268,963 published works and a cumulative cited-by count of 6,970,458, JAMA occupies a central position in the medical literature. Its h-index of 998 and a two-year mean citedness of approximately 7.96 signal the sustained influence its publications carry across the research community. JAMA is not open access, which means authors should plan for the standard subscription-based access model when considering their submission. Readers of JAMA include clinicians, researchers, public health professionals, and health policy analysts, an audience that expects rigorous methodology, clear clinical relevance, and transparent reporting.

02 Reporting Standards

Clinical and biomedical research submitted to high-impact general medical journals is expected to conform to established reporting frameworks. These standards exist not to create bureaucratic overhead, but to ensure that published findings are interpretable, reproducible, and comparable across studies.

For randomized controlled trials, the CONSORT (Consolidated Standards of Reporting Trials) guidelines provide a structured checklist and flow diagram that help authors report participant allocation, blinding procedures, and outcome data completely. For systematic reviews and meta-analyses, PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) sets expectations for literature search documentation, study selection, and synthesis methods. Observational studies (cohort, case-control, and cross-sectional designs) are covered by STROBE (Strengthening the Reporting of Observational Studies in Epidemiology), which addresses how exposure and outcome definitions, confounding, and selection bias should be disclosed.

Given JAMA's strong emphasis on medicine and health professions research, authors working in any of these study designs should treat adherence to the relevant reporting framework as a baseline requirement, not an optional enhancement. Reviewers at journals of this caliber are familiar with these checklists and will notice omissions. Completing the appropriate checklist before submission, and referencing it explicitly in your methods section, signals methodological maturity and reduces the likelihood of a desk rejection or a major revision request on procedural grounds.

03 Common Methodology Concerns

Manuscripts submitted to JAMA and journals of comparable standing in clinical medicine are routinely scrutinized for a cluster of methodological issues that, if unaddressed, can derail an otherwise strong paper. One of the most common points of reviewer critique involves adherence to reporting guidelines: authors frequently submit work that does not fully comply with CONSORT, STROBE, or PRISMA standards, leaving gaps in how interventions, exposures, or search strategies are described. Closely related is the question of sample size justification: reviewers expect to see a formal power analysis that explains how the study was sized to detect a clinically meaningful effect, and manuscripts that omit this or treat it superficially invite skepticism about whether the study was adequately powered to support its conclusions.

Statistical rigor extends beyond sample size. The handling of missing data is a persistent concern: authors should specify their approach, whether multiple imputation, complete-case analysis, or another method, and justify it relative to the missing-data mechanism. For trials, intention-to-treat analysis is the expected default, and deviations from it require explicit justification. Equally important is the clarity of blinding, randomization, and allocation concealment procedures. These elements are foundational to internal validity in experimental designs, and vague descriptions such as "patients were randomized" without specifying the method are routinely flagged. For manuscripts with a pharmacological component, reviewers additionally expect dose-response curves supported by appropriate positive controls, and selectivity profiling against relevant off-target panels. Omitting these leaves efficacy and safety claims inadequately substantiated. Addressing all of these concerns before submission, rather than in response to reviewer comments, substantially improves a manuscript's chances of advancing through review.

04 Recent Representative Work

The following papers, published in JAMA in 2025, illustrate the range of clinical and biomedical topics the journal covers:

These recent publications reflect JAMA's breadth across oncology, neurology, gynecology, and methodology, and they show the journal's continued investment in both clinical trial reporting standards and disease-specific clinical science.

05 Pre-Submission Checklist

06 How PeerPanel Reviews Your Manuscript

Before your manuscript reaches JAMA's editorial team, PeerPanel runs it past five specialist agents, each focused on a distinct dimension of manuscript quality.

07 Where to Find Author Guidelines

For formatting requirements, word limits, figure specifications, reference style, and submission procedures, consult the official author instructions on the JAMA homepage directly. These guidelines are maintained by the journal's editorial office and represent the authoritative source for submission requirements. PeerPanel does not reproduce or summarize journal-specific submission policies. The official instructions should always be your primary reference for these details.